An investigational oral drug that targets RAS, the dominant oncogenic driver in pancreatic cancer, nearly doubled overall survival compared with common second-line chemotherapy regimens in patients ...

*All products featured on *Vogue are independently selected by our editors. However, we may earn affiliate revenue on this article and commission when you buy something. If you were to ask Jennifer ...